Healthcare Industry News: HSMN NewsFeed
News Release - March 15, 2017
Smith & Nephew previews NAVIO(TM) Robotics-assisted Total Knee Application at AAOS ahead of full market release in Q2 2017LONDON, March 14, 2017 -- (Healthcare Sales & Marketing Network) -- Smith & Nephew (NYSE: SNN; LSE: SN), the global medical technology business, today announces the upcoming full market release of its NAVIO hand-held robotics-assisted total knee arthroplasty (TKA) system. Smith & Nephew will be hosting live hands-on demonstrations for surgeons at the 2017 Annual American Academy of Orthopaedic Surgeons meeting in San Diego, CA, March 15-17 (booth # 5133).
The NAVIO Surgical System total knee application is expected to enter full market release in the second quarter of 2017, 510(k) pending, with Smith & Nephew's JOURNEY II, LEGION and GENESIS II Total Knee Systems.
The NAVIO robotic-assisted total knee application is designed to deliver consistent and accurate results through the utilization of a surgeon controlled robotics-assisted hand piece, coupled with NAVIO specific cut guides. This unique combination yields an intuitive and efficient workflow for the entire surgical team. In addition, the versatile NAVIO planning software enables precise implant alignment and ligament balance, without the need for a pre-operative CT scan. Eliminating the dependency on pre-operative imaging allows the surgeon to seamlessly plan for either a unicompartmental or total knee procedure at the time of surgery.
"I have experience with several robotic systems and my experience with the NAVIO Surgical System has been phenomenal. Both NAVIO UKA and TKA applications allow me freedom as a surgeon, unlike other robotic options, because it is imageless. I can easily plan and correct for significant deformities and retained hardware with confidence. I love the direct interface with the system itself, putting me back in control.
Additionally, the cost of the system including the capital investment, lack of advanced imaging and its portability make it affordable for both hospitals and ASCs" says Jimmy Chow, M.D, Director of Orthopaedics: Hip & Joint, Phoenix St. Luke's Medical Center.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2016 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our website www.smith-nephew.com, follow @SmithNephewplc on Twitter or visit SmithNephewplc on Facebook.com.
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
Source: Smith & Nephew
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsNew Q-FIX(TM) CURVED, Q-FIX MINI and SUTUREFIX CURVED All-Suture Anchor Systems help surgeons access challenging pathology while improving the quality of shoulder and hip repairs
Smith & Nephew announces full commercial release of JOURNEY(TM) II XR Total Knee Arthroplasty
Smith & Nephew's Episode of Care Assurance Program (eCAP) reduces hospital readmission following total joint replacement surgery